Italfarmaco Group
- Biotech or pharma, therapeutic R&D
Focus for this conference is:
- In-licensing of late stage assets for markets mainly in EU in niche areas
- In-licensing of late stage assets with rare / orphan indications, especially in the neuromuscolar space for Europe and USA
- Out-licensing: R&D assets in the available geographies
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}